Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL

Leukemia. 2001 Feb;15(2):280-2. doi: 10.1038/sj.leu.2402020.

Authors

K Seeger¹, S Viehmann, D Buchwald, J Harbott, M Schrappe, J Stary, G Henze, J Trka

Affiliation

¹ Dept of Pediatric Oncology/Hematology, Charité Medical Center, Berlin, Germany.

PMID: 11236946
DOI: 10.1038/sj.leu.2402020

No abstract available

Publication types

Historical Article
Research Support, Non-U.S. Gov't

MeSH terms

Core Binding Factor Alpha 2 Subunit
History, Modern 1601-
Humans
Immunophenotyping
Monitoring, Physiologic*
Oncogene Proteins, Fusion / genetics*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Recurrence
Treatment Outcome*

Substances

Core Binding Factor Alpha 2 Subunit
Oncogene Proteins, Fusion
TEL-AML1 fusion protein